TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $424,767.07 in interest accrued up to December 31, 2021 on all five of the deferred convertible notes outstanding and disclosed in the Company’s financial statements (the “Notes”).
Shares for Interest Debt Settlement
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
